BMY vs ELTX
BMY: Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse modalities like biologics and CAR-T cell technology. ELTX: Elicio develops lymph node-targeted "off-the-shelf" cancer immunotherapies using proprietary AMP technology to generate robust T cell responses against common KRAS mutations in pancreatic, colorectal, and other solid tumors.
Side-by-side fundamentals
| Metric | BMY | ELTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $60.76 | $3.12 | |
| Market cap as of 2026-07-23 | $124.9B | $73M | |
| P/E as of 2026-07-23 | 20.91 | n/a | |
| PEG as of 2026-07-23 | -4.29 | n/a | |
| Net margin as of 2026-07-23 | +12.3% | -81.5% | BMY higher |
| Gross margin as of 2026-07-23 | +53.7% | +98.5% | ELTX higher |
| Operating margin as of 2026-07-23 | +17.1% | -83.0% | BMY higher |
| ROE as of 2026-07-23 | +41.6% | -977.7% | BMY higher |
| ROA as of 2026-07-23 | +8.7% | -151.1% | BMY higher |
| Debt / equity as of 2026-07-23 | 2.22 | 5.75 | BMY lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.8% | -91.9% | BMY higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | -10.6% | BMY higher |
| Dividend yield as of 2026-07-23 | +4.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.23 | 1.30 | |
| 1-year return as of 2026-07-22 close | +26.5% | -66.7% | BMY higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.